Phenotypic and Imaging Spectrum Associated With WDR45.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
08 2020
Historique:
received: 27 08 2019
revised: 29 01 2020
accepted: 01 03 2020
pubmed: 11 5 2020
medline: 16 6 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

Mutations in the X-linked gene WDR45 cause neurodegeneration with brain iron accumulation type 5. Global developmental delay occurs at an early age with slow progression to dystonia, parkinsonism, and dementia due to progressive iron accumulation in the brain. We present 17 new cases and reviewed 106 reported cases of neurodegeneration with brain iron accumulation type 5. Detailed information related to developmental history and key time to event measures was collected. Within this cohort, there were 19 males. Most individuals were molecularly diagnosed by whole-exome testing. Overall 10 novel variants were identified across 11 subjects. All individuals were affected by developmental delay, most prominently in verbal skills. Most individuals experienced a decline in motor and cognitive skills. Although most individuals were affected by seizures, the spectrum ranged from provoked seizures to intractable epilepsy. The imaging findings varied as well, often evolving over time. The classic iron accumulation in the globus pallidus and substantia nigra was noted in half of our cohort and was associated with older age of image acquisition, whereas myelination abnormalities were associated with younger age. WDR45 mutations lead to a progressive and evolving disorder whose diagnosis is often delayed. Developmental delay and seizures predominate in early childhood, followed by a progressive decline of neurological function. There is variable expressivity in the clinical phenotypes of individuals with WDR45 mutations, suggesting that this gene should be considered in the diagnostic evaluation of children with myelination abnormalities, iron deposition, developmental delay, and epilepsy depending on the age at evaluation.

Sections du résumé

BACKGROUND
Mutations in the X-linked gene WDR45 cause neurodegeneration with brain iron accumulation type 5. Global developmental delay occurs at an early age with slow progression to dystonia, parkinsonism, and dementia due to progressive iron accumulation in the brain.
METHODS
We present 17 new cases and reviewed 106 reported cases of neurodegeneration with brain iron accumulation type 5. Detailed information related to developmental history and key time to event measures was collected.
RESULTS
Within this cohort, there were 19 males. Most individuals were molecularly diagnosed by whole-exome testing. Overall 10 novel variants were identified across 11 subjects. All individuals were affected by developmental delay, most prominently in verbal skills. Most individuals experienced a decline in motor and cognitive skills. Although most individuals were affected by seizures, the spectrum ranged from provoked seizures to intractable epilepsy. The imaging findings varied as well, often evolving over time. The classic iron accumulation in the globus pallidus and substantia nigra was noted in half of our cohort and was associated with older age of image acquisition, whereas myelination abnormalities were associated with younger age.
CONCLUSIONS
WDR45 mutations lead to a progressive and evolving disorder whose diagnosis is often delayed. Developmental delay and seizures predominate in early childhood, followed by a progressive decline of neurological function. There is variable expressivity in the clinical phenotypes of individuals with WDR45 mutations, suggesting that this gene should be considered in the diagnostic evaluation of children with myelination abnormalities, iron deposition, developmental delay, and epilepsy depending on the age at evaluation.

Identifiants

pubmed: 32387008
pii: S0887-8994(20)30084-9
doi: 10.1016/j.pediatrneurol.2020.03.005
pmc: PMC7387198
mid: NIHMS1591926
pii:
doi:

Substances chimiques

Carrier Proteins 0
WDR45 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-62

Subventions

Organisme : NINDS NIH HHS
ID : K23 NS114113
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001879
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Am J Med Genet A. 2014 Sep;164A(9):2388-90
pubmed: 25044655
Neurol Genet. 2018 Mar 27;4(2):e227
pubmed: 29600274
J Neurol. 2017 May;264(5):1020-1022
pubmed: 28361255
Am J Hum Genet. 2012 Dec 7;91(6):1144-9
pubmed: 23176820
Am J Med Genet A. 2016 Feb;170A(2):322-328
pubmed: 26481852
J Hum Genet. 2016 Jul;61(7):653-61
pubmed: 27030146
Mov Disord. 2013 Mar;28(3):397-9
pubmed: 23390121
Handb Clin Neurol. 2018;147:293-305
pubmed: 29325618
J Hum Genet. 2014 May;59(5):292-5
pubmed: 24621584
Epileptic Disord. 2015 Dec;17(4):467-72
pubmed: 26609730
Mov Disord Clin Pract. 2018 Nov 09;6(1):51-56
pubmed: 30746416
No To Hattatsu. 2016 May;48(3):209-12
pubmed: 27349085
J Clin Neurol. 2015 Jul;11(3):289-91
pubmed: 26022463
Front Neurol. 2017 Aug 21;8:385
pubmed: 28878728
Int Rev Neurobiol. 2013;110:85-90
pubmed: 24209435
Neurol Genet. 2016 Dec 05;3(1):e124
pubmed: 27957548
Mol Genet Metab Rep. 2019 Jun 19;20:100483
pubmed: 31293896
Parkinsonism Relat Disord. 2019 Apr;61:231-233
pubmed: 30455156
Am J Med Genet A. 2014 Dec;164A(12):3095-9
pubmed: 25263061
Nat Genet. 2013 Apr;45(4):445-9, 449e1
pubmed: 23435086
Brain Dev. 2013 May;35(5):458-61
pubmed: 22892189
Neuropediatrics. 2016 Apr;47(2):123-7
pubmed: 26859818
Neuromolecular Med. 2019 Mar;21(1):54-59
pubmed: 30612247
PLoS Genet. 2014 Oct 30;10(10):e1004772
pubmed: 25356899
Eur J Hum Genet. 2016 Apr;24(4):615-8
pubmed: 26173968
Clin Genet. 2016 Dec;90(6):560-562
pubmed: 27681470
Mol Genet Genomic Med. 2019 Sep;7(9):e858
pubmed: 31332960
Eur J Hum Genet. 2016 Jul;24(7):1080-3
pubmed: 26577041
Ann Neurol. 2016 Jun;79(6):1031-1037
pubmed: 27159321
Brain Dev. 2017 Oct;39(9):804-807
pubmed: 28551038
Autophagy. 2020 Mar;16(3):531-547
pubmed: 31204559
Ann Neurol. 2014 Oct;76(4):473-83
pubmed: 25131622
Neuropediatrics. 2020 Feb;51(1):22-29
pubmed: 31505688
Neurobiol Aging. 2015 May;36(5):2004.e9-2004.e15
pubmed: 25744623
Eur J Med Genet. 2019 Feb;62(2):149-160
pubmed: 29981852
Tremor Other Hyperkinet Mov (N Y). 2017 Aug 8;7:465
pubmed: 29082105
Mov Disord. 2014 Apr;29(4):574-5
pubmed: 24610255
Mov Disord Clin Pract. 2015 Mar 30;2(2):190-191
pubmed: 30713893
Eur J Med Genet. 2015 Aug;58(8):381-6
pubmed: 26096995
Pediatrics. 2015 Sep;136(3):e714-7
pubmed: 26240209
Traffic. 2019 May;20(5):325-345
pubmed: 30843302
Front Pediatr. 2017 Oct 12;5:219
pubmed: 29075622
Clin Case Rep. 2018 Jan 04;6(2):353-362
pubmed: 29445477
Brain. 2013 Jun;136(Pt 6):1708-17
pubmed: 23687123
Am J Case Rep. 2018 Oct 20;19:1249-1252
pubmed: 30341275
Neurol Clin Neurosci. 2017 Jul;5(4):131-133
pubmed: 28932395
Ann Rehabil Med. 2017 Oct;41(5):851-857
pubmed: 29201825
Parkinsonism Relat Disord. 2014 Mar;20(3):332-6
pubmed: 24368176
Eur J Med Genet. 2020 Mar;63(3):103765
pubmed: 31536831
Cureus. 2019 Aug 16;11(8):e5404
pubmed: 31632858
Am J Med Genet A. 2017 May;173(5):1444-1446
pubmed: 28371320
J Neurol Sci. 2015 Feb 15;349(1-2):105-9
pubmed: 25592411
Am J Med Genet A. 2018 May;176(5):1049-1054
pubmed: 29681108
Transl Sci Rare Dis. 2018 Apr 13;3(1):49-53
pubmed: 29682453
Mol Cell Probes. 2016 Feb;30(1):44-9
pubmed: 26790960
Neurol Clin Pract. 2014 Apr;4(2):175-177
pubmed: 24790802
Epilepsia. 2018 Jan;59(1):e5-e13
pubmed: 29171013
Seizure. 2019 Oct;71:245-246
pubmed: 31466010
Hum Mutat. 2016 Aug;37(8):804-11
pubmed: 27159028
Eur J Med Genet. 2017 Oct;60(10):521-526
pubmed: 28711740

Auteurs

Laura A Adang (LA)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address: adangl@email.chop.edu.

Amy Pizzino (A)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Alka Malhotra (A)

Illumina Clinical Services Laboratory, Illumina, Inc., San Diego, California.

Holly Dubbs (H)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Catherine Williams (C)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Omar Sherbini (O)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Anna-Kaisa Anttonen (AK)

Folkhälsan Research Center, Helsinki, Finland; Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Gaetan Lesca (G)

Department of Medical genetics, Lyon University Hospital, Bron, France.

Tarja Linnankivi (T)

Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Chloé Laurencin (C)

Hôpital Neurologique Pierre Wertheimer, Bron, France.

Matthieu Milh (M)

Aix-Marseille Université, Marseille, France.

Charles Perrine (C)

Hôpital de La Salpêtrière, Paris, France.

Christian P Schaaf (CP)

Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.

Anne-Lise Poulat (AL)

Department of Pediatric Neurology, Lyon University Hospital, Bron, France.

Dorothee Ville (D)

Department of Pediatric Neurology, Lyon University Hospital, Bron, France.

Tanner Hagelstrom (T)

Illumina Clinical Services Laboratory, Illumina, Inc., San Diego, California.

Denise L Perry (DL)

Illumina Clinical Services Laboratory, Illumina, Inc., San Diego, California.

Ryan J Taft (RJ)

Illumina Clinical Services Laboratory, Illumina, Inc., San Diego, California.

Amy Goldstein (A)

Division of Metabolism, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Arastoo Vossough (A)

Division of Neuroradiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Ingo Helbig (I)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Adeline Vanderver (A)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH